Alan Fuhrman - 01 Jan 2023 Form 4 Insider Report for Tyra Biosciences, Inc. (TYRA)

Role
Chief Financial Officer
Signature
/s/ Ali D. Fawaz, Attorney-in-Fact
Issuer symbol
TYRA
Transactions as of
01 Jan 2023
Net transactions value
$0
Form type
4
Filing time
03 Jan 2023, 16:01:20 UTC
Previous filing
31 May 2022
Next filing
25 May 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TYRA Stock Option (Right to Buy) Award $0 +32,800 $0.000000 32,800 01 Jan 2023 Common Stock 32,800 $7.60 Direct F1, F2
transaction TYRA Stock Option (Right to Buy) Award $0 +328,000 $0.000000 328,000 01 Jan 2023 Common Stock 328,000 $7.60 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option shall vest on January 1, 2024, and 1/36th of the remaining number of shares subject to the option vest monthly thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
F2 The option vests based on achievement of a performance objective.